1. Scrip
  2. >>R&D
  3. >>Clinical Trials

89bio’s FGF21 Analog May Offer Fibrosis Benefit In Cirrhotic NASH Patients

 
• By Joseph Haas

At AASLD, 89bio presented subgroup analysis from its successful Phase IIb NASH study indicating that the drug may meaningfully reduce fibrosis even in the sickest patients, those with cirrhosis.

Cirrhotic liver
89bio's pegozafermin shows fibrosis reduction in small subgroup of cirrhotic NASH patients • Source: Shutterstock

Perhaps already best positioned in the competitive FGF21 analog class in non-alcoholic steatohepatitis development, 89bio, Inc. bolstered its positioning with a late-breaker presentation on 12 November at the American Association for the Study of Liver Disease meeting with subgroup analysis from its successful Phase IIb study of pegozafermin showing that the weekly injectable drug might offer fibrosis benefit in the sickest patients, those with cirrhosis (F4 fibrosis).

Key Takeaways

  • 89bio presented Phase IIb subgroup analysis at the AASLD conference suggesting a fibrosis-reduction benefit for pegozafermin in cirrhotic NASH patients.

89bio is competing primarily with Akero Therapeutics, Inc. and its Phase II efruxifermin and privately held Boston Pharmaceuticals...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

In Brief: Gilead HIV Trials On Hold Over Safety Signal

 
• By Sushmita Panda

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

 
• By Sushmita Panda

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By Joseph Haas

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

More from R&D

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By Joseph Haas

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

NewAmsterdam’s CETP Inhibitor Improves Alzheimer’s Biomarkers

 
• By Mandy Jackson

Data from the BROADWAY trial testing LDL-C reduction in adults with ASCVD showed that obicetrapib improved Alzheimer’s disease biomarkers, including tau and amyloid. Analysts think the data could differentiate obicetrapib against competitors in the cholesterol market.

With ACIP Upheaval, Merck & Co. Among Those Left In A Lurch

 
• By Jessica Merrill and Bridget Silverman

Merck’s newly approved Enflonsia for RSV is one of the products that was expected to be recommended for use by the CDC advisory committee in June.